SEARCH

SEARCH BY CITATION

References

  • 1
    Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:25602572.
  • 2
    Gupta AK, McGlone M, Greenway FL, Johnson WD. Prehypertension in disease-free adults: a marker for an adverse cardiometabolic risk profile. Hypertens Res. 2010;33:905910.
  • 3
    Julius S, Nesbitt SD, Egan BM, et al. Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med. 2006;354:16851697.
  • 4
    Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in overweight people with high-normal blood pressure. The Trials of Hypertension Prevention, phase II. The Trials of Hypertension Prevention Collaborative Research Group. Arch Intern Med. 1997;157:657667.
  • 5
    Appel LJ, Moore TJ, Obarzanek E, et al. A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. N Engl J Med. 1997;336:11171124.
  • 6
    He J, Whelton PK, Appel LJ, et al. Long-term effects of weight loss and dietary sodium reduction on incidence of hypertension. Hypertension. 2000;35:544549.
  • 7
    Fuchs FD, Fuchs SC, Moreira LB, et al. Prevention of hypertension in patients with pre-hypertension: protocol for the PREVER-prevention trial. Trials. 2011;12:65.
  • 8
    Mellen PB, Gao SK, Vitolins MZ, Goff DC Jr. Deteriorating dietary habits among adults with hypertension: DASH dietary accordance, NHANES 1988–1994 and 1999–2004. Arch Intern Med. 2008;168:308314.
  • 9
    Luders S, Schrader J, Berger J, et al. The PHARAO study: prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure: a prospective, randomized, controlled prevention trial of the German Hypertension League. J Hypertens. 2008;26:14871496.
  • 10
    Bubien JK. Epithelial Na+ channel (ENaC), hormones, and hypertension. J Biol Chem. 2010;285:2352723531.
  • 11
    Pratt JH. Central role for ENaC in development of hypertension. J Am Soc Nephrol. 2005;16:31543159.
  • 12
    Su YR, Menon AG. Epithelial sodium channels and hypertension. Drug Metab Dispos. 2001;29(4 Pt 2):553556.
  • 13
    Nelson MR, Stepanek J, Cevette M, et al. Noninvasive measurement of central vascular pressures with arterial tonometry: clinical revival of the pulse pressure waveform? Mayo Clin Proc. 2010;85:460472.
  • 14
    Roman MJ, Devereux RB, Kizer JR, et al. Central pressure more strongly relates to vascular disease and outcome than does brachial pressure: the Strong Heart Study. Hypertension. 2007;50:197203.
  • 15
    Yeboah J, Folsom AR, Burke GL, et al. Predictive value of brachial flow-mediated dilation for incident cardiovascular events in a population-based study: the multi-ethnic study of atherosclerosis. Circulation. 2009;120:502509.
  • 16
    Mattace-Raso FU, van der Cammen TJ, Hofman A, et al. Arterial stiffness and risk of coronary heart disease and stroke: the Rotterdam Study. Circulation. 2006;113:657663.
  • 17
    Dong Y, Stallmann-Jorgensen IS, Pollock NK, et al. A 16-week randomized clinical trial of 2000 international units daily vitamin D3 supplementation in black youth: 25-hydroxyvitamin D, adiposity, and arterial stiffness. J Clin Endocrinol Metab. 2010;95:45844591.
  • 18
    Harris RA, Nishiyama SK, Wray DW, Richardson RS. Ultrasound assessment of flow-mediated dilation. Hypertension. 2010;55:10751085.
  • 19
    Harris RA, Pedersen-White J, Guo DH, et al. Vitamin D3 supplementation for 16 weeks improves flow-mediated dilation in overweight African-American adults. Am J Hypertens. 2011;24:557562.
  • 20
    Multiclinic comparison of amiloride, hydrochlorothiazide, and hydrochlorothiazide plus amiloride in essential hypertension. Multicenter Diuretic Cooperative Study Group. Arch Intern Med. 1981;141:482486.
  • 21
    Gombos EA, Freis ED, Moghadam A. Effects of MK-870 in normal subjects and hypertensive patients. N Engl J Med. 1966;275:12151220.
  • 22
    Katzman PL, Henningsen NC, Hulthen UL. Amiloride compared with nitrendipine in treatment of essential hypertension. J Hum Hypertens. 1988;2:147151.
  • 23
    Laragh JH. The proper use of newer diuretics. Ann Intern Med. 1967;67:607613.
  • 24
    Paterson JW, Dollery CT, Haslam RM. Amiloride hydrochloride in hypertensive patients. Br Med J. 1968;1:422423.
  • 25
    Thomas JP, Thomson WH. Comparison of thiazides and amiloride in treatment of moderate hypertension. Br Med J. 1983;286:20152018.
  • 26
    Saha C, Eckert GJ, Ambrosius WT, et al. Improvement in blood pressure with inhibition of the epithelial sodium channel in blacks with hypertension. Hypertension. 2005;46:481487.
  • 27
    Pratt JH, Eckert GJ, Newman S, Ambrosius WT. Blood pressure responses to small doses of amiloride and spironolactone in normotensive subjects. Hypertension. 2001;38:11241129.
  • 28
    Stears AJ, Woods SH, Watts MM, et al. A double-blind, placebo-controlled, crossover trial comparing the effects of amiloride and hydrochlorothiazide on glucose tolerance in patients with essential hypertension. Hypertension. 2012;59:934942.
  • 29
    Heran BS, Chen JM, Wang JJ, Wright JM. Blood pressure lowering efficacy of potassium-sparing diuretics (that block the epithelial sodium channel) for primary hypertension. Cochrane Database of Systematic Reviews. 2012;11:CD008167.
  • 30
    Matthesen SK, Larsen T, Vase H, et al. Effect of amiloride and spironolactone on renal tubular function and central blood pressure in patients with arterial hypertension during baseline conditions and after furosemide: a double-blinded, randomized, placebo-controlled crossover trial. Clin Exp Hypertens. 2013;35:313324.
  • 31
    Farquharson CA, Struthers AD. Increasing plasma potassium with amiloride shortens the QT interval and reduces ventricular extrasystoles but does not change endothelial function or heart rate variability in chronic heart failure. Heart. 2002;88:475480.
  • 32
    Jernigan NL, Drummond HA. Vascular ENaC proteins are required for renal myogenic constriction. Am J Physiol Renal Physiol. 2005;289:F891F901.
  • 33
    Drummond HA, Gebremedhin D, Harder DR. Degenerin/epithelial Na+ channel proteins: components of a vascular mechanosensor. Hypertension. 2004;44:643648.
  • 34
    Oberleithner H, Riethmuller C, Schillers H, et al. Plasma sodium stiffens vascular endothelium and reduces nitric oxide release. Proc Natl Acad Sci USA. 2007;104:1628116286.
  • 35
    Pérez FR, Venegas F, González M, et al. Endothelial epithelial sodium channel inhibition activates endothelial nitric oxide synthase via phosphoinositide 3-kinase/Akt in small-diameter mesenteric arteries. Hypertension. 2009;53:10001007.
  • 36
    Teiwes J, Toto RD. Epithelial sodium channel inhibition in cardiovascular disease. A potential role for amiloride. Am J Hypertens. 2007;20:109117.
  • 37
    Kleyman TR, Cragoe EJ. Amiloride and its analogs as tools in the study of ion transport. J Membr Biol. 1988;105:121.
  • 38
    Taddei S, Mattei P, Virdis A, et al. Effect of potassium on vasodilation to acetylcholine in essential hypertension. Hypertension. 1994;23:485490.
  • 39
    Bull MB, Laragh JH. Amiloride. A potassium-sparing natriuretic agent. Circulation. 1968;37:4553.
  • 40
    Warnock DG, Bell PD. Improvement of blood pressure with inhibition of the epithelial sodium channel in blacks with hypertension. Hypertension. 2005;46:469470.